Prostate cancer is the most common non-skin cancer in men. Roughly 1 in 8 men will be diagnosed during their lifetime, and the actual number living with undetected prostate cancer is far higher than the diagnosed count suggests. In the United States alone, the age-adjusted incidence rate is about 122 new cases per 100,000 men among non-Hispanic white men, with rates varying sharply by race and age.
How Many Men Are Diagnosed Each Year
Prostate cancer incidence rates in the U.S. range from about 67 per 100,000 in Asian/Pacific Islander men to over 200 per 100,000 in Black men. Globally, the picture varies dramatically: estimated rates across world regions differ by a factor of 13. The highest incidence is found in Australia/New Zealand, North America, Northern Europe, and Latin America/Caribbean, while parts of Asia have significantly lower rates.
These numbers reflect diagnosed cases only. Autopsy studies paint a very different picture of how widespread prostate cancer actually is. A cross-sectional study published in the Journal of the National Cancer Institute examined prostates from men who died of unrelated causes and found cancer in 35.6% of them. Among men over 60, more than 40% had undetected prostate cancer, and the figure climbed to nearly 60% in men over 80. Most of these cancers were slow-growing and would never have caused symptoms. This gap between diagnosed and actual prevalence is one reason prostate cancer screening remains a nuanced decision.
Age Is the Biggest Risk Factor
Prostate cancer is rare before age 45. According to the CDC, only 5% of cases diagnosed in 2022 were in men aged 45 to 54. The bulk of diagnoses, 52%, occurred in men between 55 and 69. Another 43% were in men 70 or older. Incidence peaks in the 70 to 74 age group, where rates reach about 764 per 100,000 men.
This age distribution matters for understanding your personal risk. A man in his 40s has a very different probability than a man in his 70s, even though both fall under the same “1 in 8 lifetime” statistic. The lifetime number is an average that blends decades of low risk with a steep climb in later life.
Race and Ethnicity Shape Risk Significantly
The disparity in prostate cancer rates across racial groups is one of the largest in all of oncology. The age-adjusted incidence rate for Black men is about 200 per 100,000, roughly 65% higher than the rate for white men (122 per 100,000) and three times the rate for Asian/Pacific Islander men (67 per 100,000). Hispanic men fall in between at around 93 per 100,000.
The gap extends to mortality. The death rate for Black men is 36.2 per 100,000, double the rate for white men (18.1) and more than four times the rate for Asian/Pacific Islander men (8.7). These disparities stem from a combination of biological factors, differences in access to screening and treatment, and socioeconomic barriers. Black men are also more likely to be diagnosed at a younger age and with more aggressive disease.
Despite the higher incidence and mortality, five-year survival rates across all stages are relatively close between groups: 97.9% for white men, 95.6% for Black men, and 95.1% to 95.7% for other groups. The survival gap widens considerably for cancers diagnosed at a distant (metastatic) stage, where five-year survival ranges from about 29% for white men to 42% for Asian/Pacific Islander men.
Family History and Genetic Mutations
Having a father or brother with prostate cancer roughly doubles your risk. The inherited component becomes even more pronounced in men who carry mutations in the BRCA genes, which are better known for their link to breast and ovarian cancer in women.
Men with a harmful BRCA2 mutation have a 19% to 61% chance of developing prostate cancer by age 80, compared to about 10.6% for men in the general population. BRCA1 mutations carry a smaller but still elevated risk of 7% to 26% by age 80. BRCA2-linked prostate cancers also tend to be more aggressive. Men with a strong family history of prostate, breast, or ovarian cancer may benefit from genetic counseling to understand whether testing makes sense for them.
Survival Rates Are Among the Highest of Any Cancer
Prostate cancer has one of the best overall survival profiles in oncology. When all stages are combined, the five-year relative survival rate exceeds 95% across every racial and ethnic group studied. The majority of prostate cancers are caught while still localized to the prostate or nearby tissue, and at those stages survival is extremely high.
The picture changes for cancer that has already spread to distant parts of the body at diagnosis. Five-year survival for distant-stage prostate cancer drops to roughly 29% to 42%, depending on race and ethnicity. Death rates are highest among men between 75 and 84 and among those diagnosed with advanced disease. Still, even distant-stage survival has improved over recent decades thanks to newer treatment options.
Why Rates Vary So Much Worldwide
Prostate cancer incidence differs by a factor of 13 across world regions. Countries with widespread PSA screening programs, like the U.S. and Australia, detect far more cases, including many slow-growing tumors that would never cause harm. This screening effect inflates incidence numbers without necessarily reflecting a true difference in how often the disease develops. The autopsy data showing similar cancer prevalence in Caucasian and Asian men (37.3% vs. 35.0%) despite very different diagnosed rates supports this idea. Much of the international variation is a story about detection, not just biology.
That said, diet, lifestyle, and genetic ancestry do play real roles. Regions with higher consumption of animal fats and lower physical activity levels tend to report higher rates, though separating these effects from screening differences is difficult.